

# Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/I4407893B58EN.html>

Date: October 2018

Pages: 118

Price: US\$ 3,500.00 (Single User License)

ID: I4407893B58EN

## Abstracts

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H2 2018

### SUMMARY

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 39 molecules. Out of which approximately 35 molecules are developed by companies and remaining by the universities/institutes. The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity.

The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 9, 3, 14 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report

covers products from therapy areas Oncology, Dermatology, Immunology and Metabolic Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Metastatic Melanoma, Glioblastoma Multiforme (GBM), Bladder Cancer, Colon Cancer, Gastric Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Alopecia, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Ependymoma, Glioma, Gliosarcoma, Hematological Tumor, Hepatocellular Carcinoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Liver Cancer, Malignant Glioma, Medulloblastoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ocular Melanoma, Ovarian Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Psoriasis, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Type 1 Diabetes (Juvenile Diabetes).

Furthermore, this report also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under

development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects

The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development

BeiGene Ltd

BirchBioMed Inc

Bristol-Myers Squibb Co

CanBas Co Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Incyte Corp

Innovent Biologics Inc

IO Biotech ApS

iTeos Therapeutics SA

Jiangsu Hengrui Medicine Co Ltd

Kyowa Hakko Kirin Co Ltd

Luye Pharma Group Ltd

Merck & Co Inc

Netherlands Translational Research Center BV

NewLink Genetics Corp

Phenex Pharmaceuticals AG

Regen BioPharma Inc

Systimmune Inc

Tempest Therapeutics Inc

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Drug Profiles

(IO-102 + IO-103) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AI-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-0015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BEBT-303 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-5777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLH-1131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dCellVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DN-1406131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EOS-200271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epacadostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTI-1090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

indoximod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KHK-2455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linrodostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-01013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3381916 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-7162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLG-802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXD-26116 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-70099 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit IDO1 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile

Product Description



Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO-1 for Lewis Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO1 and DNA for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPST-8844 - Drug Profile

## Product Description

## Mechanism Of Action

## R&D Progress

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Discontinued Products

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones

## Featured News & Press Releases

Oct 01, 2018: IO Biotech doses first patient in Phase I/II IO102 and Keytruda trial

Jul 31, 2018: Approval for clinical trial for class I new chemical drug—Anti-Tumor innovative drug (LY01013) in China

Jul 02, 2018: NewLink reports new Phase I positive data from trial for DIPG

Jun 20, 2018: NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting

Jun 06, 2018: De Novo Pharmatech receives approval to initiate clinical trials in China with IDO1/TDO2 inhibitor DN1406131

Jun 04, 2018: NewLink Genetics Announces Final Results from Two Phase 2 Studies of Indoximod Presented at ASCO 2018

May 16, 2018: NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018

Apr 25, 2018: NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting

Apr 25, 2018: Incyte to Present Data on Epcadostat at the 2018 ASCO Annual Meeting

Apr 15, 2018: NewLink Genetics Announces Initial Phase 1 Data with Indoximod Plus Radiation and Chemotherapy for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Presented During AACR Plenary

Apr 06, 2018: NewLink Genetics Announces Review of Clinical Programs

Apr 06, 2018: Incyte and Merck Provide Update on Phase 3 Study of Epcadostat in Combination with KEYTRUDA (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

Mar 14, 2018: NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting

Feb 09, 2018: iTeos Therapeutics Provides Update on its IDO1 Inhibitor EOS200271 at Molecular Medicine Tri-Conference

Jan 08, 2018: NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3

Pivotal Trial of Indoximod Plus PD-1 Inhibitors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018  
Number of Products under Development by Companies, H2 2018  
Number of Products under Development by Companies, H2 2018 (Contd.1)  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Products under Development by Companies, H2 2018 (Contd.2), H2 2018  
Products under Development by Companies, H2 2018 (Contd.3), H2 2018  
Products under Development by Companies, H2 2018 (Contd.4), H2 2018  
Number of Products under Investigation by Universities/Institutes, H2 2018  
Products under Investigation by Universities/Institutes, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by BeiGene Ltd, H2 2018  
Pipeline by BirchBioMed Inc, H2 2018  
Pipeline by Bristol-Myers Squibb Co, H2 2018  
Pipeline by CanBas Co Ltd, H2 2018  
Pipeline by Eli Lilly and Co, H2 2018  
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018  
Pipeline by Incyte Corp, H2 2018  
Pipeline by Innovent Biologics Inc, H2 2018  
Pipeline by IO Biotech ApS, H2 2018  
Pipeline by iTeos Therapeutics SA, H2 2018  
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018  
Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018  
Pipeline by Luye Pharma Group Ltd, H2 2018  
Pipeline by Merck & Co Inc, H2 2018  
Pipeline by Netherlands Translational Research Center BV, H2 2018  
Pipeline by NewLink Genetics Corp, H2 2018  
Pipeline by Phenex Pharmaceuticals AG, H2 2018  
Pipeline by Regen BioPharma Inc, H2 2018

Pipeline by Systimmune Inc, H2 2018  
Pipeline by Tempest Therapeutics Inc, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018  
Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Top 10 Indications, H2 2018  
Number of Products by Mechanism of Actions, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Routes of Administration, H2 2018  
Number of Products by Stage and Routes of Administration, H2 2018  
Number of Products by Molecule Types, H2 2018  
Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

BeiGene Ltd  
BirchBioMed Inc  
Bristol-Myers Squibb Co  
CanBas Co Ltd  
Eli Lilly and Co  
F. Hoffmann-La Roche Ltd  
Incyte Corp  
Innovent Biologics Inc  
IO Biotech ApS  
iTeos Therapeutics SA  
Jiangsu Hengrui Medicine Co Ltd  
Kyowa Hakko Kirin Co Ltd  
Luye Pharma Group Ltd  
Merck & Co Inc  
Netherlands Translational Research Center BV  
NewLink Genetics Corp  
Phenex Pharmaceuticals AG  
Regen BioPharma Inc  
Systimmune Inc  
Tempest Therapeutics Inc

## I would like to order

Product name: Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/I4407893B58EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I4407893B58EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

